Dr. Neil Rofsky, director of MRI at Beth Israel Deaconess Medical Center, Harvard Medical School, in Boston, Mass., has used the MEDRAD eCoil on a GE 3.0T MR scanner for the past several years. "The MEDRAD 3.0T eCoil can aid in the earlier diagnosis of prostate cancer and optimize the treatment options for patients," said Rofsky.

John Kurhanewicz, Ph.D., director of the Prostate Imaging Group and Biomedical NMR Lab and professor of radiology and pharmaceutical chemistry at the University of California, San Francisco (UCSF) School of Medicine, has observed similar results on a GE scanner. "The increased spectral dispersion obtainable at 3.0T allows for better
quantification of metabolites, notably the elevation of choline resonance, which has emerged as the most specific marker for prostate
cancer," said Kurhanewicz.

The Prostate eCoil is also available for 1.5T magnet strength environments and is one of MEDRAD's Leading ImageTM MR Coil products.

About MEDRAD
MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body.
Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2005 revenues were $411 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a U.S. affiliate of Schering AG, Germany (FSE:SCH; NYSE:SHR). For more information, visit MEDRAD's website at www.medrad.com.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. GE Healthcare's expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest.

GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease,
neurological diseases, and other conditions earlier. GE Healthcare's vision for the future is to enable a new "early health" model of care
focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare
is a $15 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 43,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit their website at www.gehealthcare.com

Back to HCB News

More Industry Headlines